Myths vs facts: CYP2C19 and Darmgesundheit

The link between CYP2C19 and gut health is often misunderstood. CYP2C19 is a liver enzyme that metabolizes drugs like proton pump inhibitors (PPIs) and clopidogrel. Genetic variants (*2, *3, *17) classify individuals as poor, intermediate, normal, or ultrarapid metabolizers. Myth: CYP2C19 variants directly cause gut issues like IBS, inflammation, or dysbiosis. Fact: The evidence for a direct effect on gut health is weak. PPIs, whose efficacy and side effects are influenced by CYP2C19 metabolism, can alter the gut microbiome when used long-term. However, this is an indirect drug effect, not a direct genetic effect on the gut. A DNA test for CYP2C19 is useful for drug dosing but not for diagnosing gut health. For gut-related concerns, microbiome testing, dietary assessment, and clinical evaluation are more appropriate. Evidence: mechanistic/unclear for direct gut health claims.